semaglutide and cardiovascular outcomes in obesity without diabetes journal club 2.4 mg delivered a statistically significant 20% risk reduction major adverse events – REGENHEALTHSOLUTIONS (RHS) Weight loss and cardiovascular disease

Why Medically Supervised Weight Loss Matters Greater safety and fewer risks compared to unsupervised plans A tailored approach that fits your health profile and lifestyle Support for long-term results, not just short-term changes Access to experts who understand the medical and emotional aspects of weight loss What are GLP-1 Weight Loss Injections

Tirzepatide (Injections and Oral) Tirzepatide is a dual-action GIP and GLP-1 receptor agonist that targets appetite and blood sugar regulation simultaneously

Medication is prepared by state-licensed compounding pharmacies separate from both the platform and the clinicians

It can happen when the body breaks down fats too quickly